

Study Results Javelin Renal 101

A study of avelumab with axitinib versus sunitinib
in advanced renal cell cancer


source : www.esmo.org/Press-Office/Press-Releases/Javelin101-renal-cancer-immunotherapy-Motzer



886
Patients




273
Trial Sites




21
Countries

Trial Design




Objective Response Rate (ORR)



51% vs 26%

% of Patients with Partial or Complete Response

Patients with PD-L1+ tumours



55% vs 26%

% of Patients with Partial or Complete Response

Progression Free Survival (Median PFS)



13.8 Months

8.4 Months


Patients with PD-L1+ tumours



13.8 Months

7.2 Months


Complete Response (CR)



3%

2%

Patients with PD-L1+ tumours



4%

2%


Overall Survival (OS)



Not Yet Available *

Side Effects

Grade 3 or Grade 4



55%

55%



© IKCC = International Kidney Cancer Coalition,
www.ikcc.org, www.10forio.info

* Overall Survival Data Has Not Yet Matured

